PMID- 20371685
OWN - NLM
STAT- MEDLINE
DCOM- 20100812
LR  - 20220330
IS  - 1557-3265 (Electronic)
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 16
IP  - 8
DP  - 2010 Apr 15
TI  - Survival of patients with newly diagnosed glioblastoma treated with radiation and 
      temozolomide in research studies in the United States.
PG  - 2443-9
LID - 10.1158/1078-0432.CCR-09-3106 [doi]
AB  - PURPOSE: Novel agents are currently combined with radiation and temozolomide (RT 
      + TMZ) in newly diagnosed glioblastoma using overall survival as the primary end 
      point. Results of these phase II studies are typically compared with the phase 
      III European Organization for Research and Treatment of Cancer (EORTC) survival 
      data that resulted in RT + TMZ becoming standard therapy. EXPERIMENTAL DESIGN: 
      The New Approaches to Brain Tumor Therapy (NABTT) Consortium assigned 365 
      patients with glioblastoma to four single-cohort studies with similar eligibility 
      criteria. Patients received RT + TMZ with talampanel (n = 72), poly-ICLC (n = 
      97), or cilengitide (n = 112) or RT + TMZ alone with monitoring of CD4 counts (n 
      = 84). Overall survival of those ages 18 to 70 years with glioblastoma was 
      compared with published EORTC data. RESULTS: NABTT and EORTC patients had 
      comparable performance status and debulking surgery. Median, 12-month, and 
      24-month survival rates for the EORTC patients (n = 287) and the comparable NABTT 
      patients receiving RT + TMZ and novel agents (n = 244) are 14.6 versus 19.6 
      months, 61% versus 81%, and 27% versus 37%, respectively. This represents a 37% 
      reduction in odds of death (P < 0.0001) through 2 years of follow-up. NABTT and 
      EORTC patients receiving only RT + TMZ had similar survival. CONCLUSIONS: Newly 
      diagnosed glioblastoma treated recently with RT + TMZ and talampanel, poly-ICLC, 
      or cilengitide had significantly longer survival than similar patients treated 
      with only RT + TMZ accrued internationally from 2000 to 2002. These differences 
      could result from the novel agents or changing patterns of care. Until the 
      reasons for these different survival rates are clarified, comparisons of outcomes 
      from phase II studies with published RT + TMZ survival data should be interpreted 
      with caution.
FAU - Grossman, Stuart A
AU  - Grossman SA
AD  - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, 
      Maryland, USA. grossman@jhmi.edu.
FAU - Ye, Xiaobu
AU  - Ye X
FAU - Piantadosi, Steven
AU  - Piantadosi S
FAU - Desideri, Serena
AU  - Desideri S
FAU - Nabors, Louis B
AU  - Nabors LB
FAU - Rosenfeld, Myrna
AU  - Rosenfeld M
FAU - Fisher, Joy
AU  - Fisher J
CN  - NABTT CNS Consortium
LA  - eng
GR  - U01 CA062475-14/CA/NCI NIH HHS/United States
GR  - U01 CA062475/CA/NCI NIH HHS/United States
GR  - UM1 CA137443/CA/NCI NIH HHS/United States
GR  - U01 CA137443/CA/NCI NIH HHS/United States
GR  - CA62475/CA/NCI NIH HHS/United States
GR  - CA137443/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20100406
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (Interferon Inducers)
RN  - 0 (Receptors, AMPA)
RN  - 0 (Snake Venoms)
RN  - 12794-10-4 (Benzodiazepines)
RN  - 25104-18-1 (Polylysine)
RN  - 4EDF46E4GI (Cilengitide)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 7KYP9TKT70 (poly ICLC)
RN  - CVS43XG1L5 (talampanel)
RN  - K679OBS311 (Carboxymethylcellulose Sodium)
RN  - O84C90HH2L (Poly I-C)
RN  - YF1K15M17Y (Temozolomide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents, Alkylating/*therapeutic use
MH  - Benzodiazepines/therapeutic use
MH  - Biomedical Research
MH  - Brain Neoplasms/drug therapy/*mortality/radiotherapy/*therapy
MH  - Carboxymethylcellulose Sodium/analogs & derivatives/therapeutic use
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - Combined Modality Therapy
MH  - Cranial Irradiation
MH  - Dacarbazine/*analogs & derivatives/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glioblastoma/drug therapy/*mortality/radiotherapy/*therapy
MH  - Humans
MH  - Interferon Inducers/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Poly I-C/therapeutic use
MH  - Polylysine/analogs & derivatives/therapeutic use
MH  - Receptors, AMPA/antagonists & inhibitors
MH  - Snake Venoms/therapeutic use
MH  - Survival Rate
MH  - Temozolomide
MH  - Treatment Outcome
MH  - United States
MH  - Young Adult
PMC - PMC2861898
MID - NIHMS182857
EDAT- 2010/04/08 06:00
MHDA- 2010/08/13 06:00
PMCR- 2011/04/15
CRDT- 2010/04/08 06:00
PHST- 2010/04/08 06:00 [entrez]
PHST- 2010/04/08 06:00 [pubmed]
PHST- 2010/08/13 06:00 [medline]
PHST- 2011/04/15 00:00 [pmc-release]
AID - 1078-0432.CCR-09-3106 [pii]
AID - 10.1158/1078-0432.CCR-09-3106 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2010 Apr 15;16(8):2443-9. doi: 10.1158/1078-0432.CCR-09-3106. 
      Epub 2010 Apr 6.